Want to see JP:6869 full AI Analyst Report?
6869 Stock Chart & Stats
¥1530.00
¥19.50(1.21%)
At close: 4:00 PM EDT
¥1530.00
¥19.50(1.21%)
Day’s Range― - ―
52-Week Range¥1,246.00 - ¥2,086.00
Previous CloseN/A
Volume1.58M
Average Volume (3M)2.38M
Market Cap
¥1.23T
Enterprise Value¥912.23K
Total Cash (Recent Filing)¥113.63B
Total Debt (Recent Filing)¥123.53B
Price to Earnings (P/E)29.6
Beta0.20
Next Earnings
Nov 11, 2026EPS Estimate
16.15Next Dividend Ex-DateN/A
Dividend Yield1.92%
Share Statistics
EPS (TTM)63.76
Shares Outstanding629,480,100
10 Day Avg. Volume2,693,210
30 Day Avg. Volume2,377,620
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)1.69
Price to Sales (P/S)1.71
P/FCF Ratio20.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,825.00Price Target Upside19.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)65.57
Revenue Forecast (FY)¥536.49B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a large equity base give Sysmex structural financial flexibility. This reduces refinancing risk, supports capital spending for instrument placements, and preserves capacity for M&A or share returns, helping the business sustain investment through cycles over the next 2–6 months.
Installed-base Consumables ModelSysmex’s instrument-plus-consumables/service model creates durable, recurring revenue and high customer retention. Installed analyzers drive predictable reagent demand and service contracts, supporting steady cash flow and margin sustainability independent of one-off instrument sales.
Healthy Operating And Free Cash FlowRobust OCF and strong FCF recovery provide internal funding for R&D, maintenance of installed base, and dividend or buyback capacity. Consistent absolute cash generation strengthens resilience to cyclical demand and underpins strategic reinvestment over the medium term.
Bears Say
Margin And ROE CompressionDeclining margins and reduced ROE indicate weakening earnings efficiency versus historical performance. Persistent margin compression can erode the cash available for reinvestment, reduce competitive flexibility on pricing or R&D, and pressure long-term returns to shareholders.
Moderate Cash ConversionOnly moderate cash conversion suggests working capital, tax, or capex drags that can amplify earnings volatility. If conversion remains constrained, it limits the translation of accounting profits into reinvestable cash, constraining growth initiatives and capital allocation flexibility.
Modest Revenue Growth & EPS DeclineLow single-digit top-line growth and a significant EPS decline point to competitive pressures, pricing or mix headwinds, or cost increases. These trends risk slower scale benefits for margins and could make sustaining investment in products and geographic expansion more challenging.
Sysmex News
6869 FAQ
What was Sysmex Corporation’s price range in the past 12 months?
Sysmex Corporation lowest stock price was ¥1246.00 and its highest was ¥2086.00 in the past 12 months.
What is Sysmex Corporation’s market cap?
Sysmex Corporation’s market cap is ¥1.23T.
When is Sysmex Corporation’s upcoming earnings report date?
Sysmex Corporation’s upcoming earnings report date is Nov 11, 2026 which is in 89 days.
How were Sysmex Corporation’s earnings last quarter?
Sysmex Corporation released its earnings results on Aug 07, 2026. The company reported ¥14.17 earnings per share for the quarter, beating the consensus estimate of ¥9.003 by ¥5.167.
Is Sysmex Corporation overvalued?
According to Wall Street analysts Sysmex Corporation’s price is currently Undervalued.
Does Sysmex Corporation pay dividends?
Sysmex Corporation pays a Annually dividend of ¥20 which represents an annual dividend yield of 1.92%. See more information on Sysmex Corporation dividends here
What is Sysmex Corporation’s EPS estimate?
Sysmex Corporation’s EPS estimate is 16.15.
How many shares outstanding does Sysmex Corporation have?
Sysmex Corporation has 629,480,100 shares outstanding.
What happened to Sysmex Corporation’s price movement after its last earnings report?
Sysmex Corporation reported an EPS of ¥14.17 in its last earnings report, beating expectations of ¥9.003. Following the earnings report the stock price went up 0.64%.
Which hedge fund is a major shareholder of Sysmex Corporation?
Currently, no hedge funds are holding shares in JP:6869
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.
6869 Stock 12 Month Forecast
Average Price Target
¥1,825.00
▲(19.28% Upside)